



85% of patients treated with darbepoetin Q2W maintained Hb in the target range.¹



Employing Darbepoetin Alfa Demonstrates Better Hb Stability With Proven Tolerability and Safety.²



Darbepoetin alfa regimen¹	Week 1	Week 2	Week 3	Week 4
Weekly	✓		✓	
Monthly	✓			



 **To Know More About Cresp! >**

Change for Better...Change to



Abbreviations

DPO: Darbepoetin alfa; EPO: Erythropoietin; Hb: Hemoglobin; QW: Once weekly; Q2W: Once every 2 weeks; rHuEPO: Recombinant human erythropoietin.

References

1. Carrera F, Burnier M. Use of darbepoetin alfa in the treatment of anaemia of chronic kidney disease: clinical and pharmaco-economic considerations. *NDT Plus*. 2009;2(Suppl_1):i9-i17. 2. Bernieh B, Abouchacra S, Boobes Y, et al. Comparison between short- and long-acting erythropoiesis-stimulating agents in hemodialysis patients: target hemoglobin, variability, and outcome. *Int Urol Nephrol*. 2014;46:453-459.

LMRC Code: GGI-CO-A1-AQS-DCVN-BANNERS-I23-0349

For the use of a Registered Medical Practitioner, Hospital or Laboratory only.

All content including: text, images, audio, or other formats were created for medical educational purposes only. Offerings for continuing education are clearly identified and the appropriate target audience is identified. This communication is restricted for the use of HCPs and must not be shared in public domain. The opinions expressed in this video are solely the views of the speaker. The presentation may contain off label usage of drug(s) aimed at educational purpose only. Dr. Reddy's Laboratories Ltd including but not limited its Affiliates strictly does not recommend any off label usage of its marketing products. Prior to treatment kindly refer to the latest prescribing information approved by the local authorities. No part of this content may be used, reproduced, transmitted or stored in any form without the written permission of Dr. Reddy's.